Immatics (IMTX) Income from Continuing Operations (2019 - 2025)
Immatics recorded quarterly Income from Continuing Operations of 46184590.49 in Q4 2025, up 22.23% quarter-over-quarter from 59386829.59 in Q3 2025, and down 181.53% year-over-year from 56647310.76 in Q4 2024.
Immatics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 46184590.49 for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 181.53% year-over-year to 46184590.49; the TTM figure through Dec 2025 stood at 231482704.1 (down 746.64% YoY), while the FY2025 annual figure was 226442407.73, down 871.3% from the prior year.
- Income from Continuing Operations came in at 46184590.49 for Q4 2025 at Immatics, up from 59386829.59 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 96141693.63 in Q1 2022 to a low of 81897283.43 in Q2 2025.
- A 5-year average of 17099111.81 and a median of 23996855.1 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations surged 449.38% in 2022 and tumbled 9127.64% in 2025, its largest moves.
- Immatics' Income from Continuing Operations stood at 19203840.36 in 2021, then soared by 129.87% to 5736850.94 in 2022, then sank by 590.4% to 28133676.74 in 2023, then surged by 301.35% to 56647310.76 in 2024, then plunged by 181.53% to 46184590.49 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 46184590.49, 59386829.59, and 81897283.43 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | -46.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -46.18 Mn |
| Sep 30, 2025 | -59.39 Mn |
| Jun 30, 2025 | -81.90 Mn |
| Mar 31, 2025 | -44.01 Mn |
| Dec 31, 2024 | 56.65 Mn |
| Sep 30, 2024 | 657,833.48 |
| Jun 30, 2024 | -19.07 Mn |
| Mar 31, 2024 | -2.43 Mn |
| Dec 31, 2023 | -28.13 Mn |
| Sep 30, 2023 | -28.84 Mn |
| Jun 30, 2023 | -26.80 Mn |
| Mar 31, 2023 | -21.20 Mn |
| Dec 31, 2022 | 5.74 Mn |
| Sep 30, 2022 | -19.98 Mn |
| Jun 30, 2022 | -12.47 Mn |
| Mar 31, 2022 | 96.14 Mn |
| Dec 31, 2021 | -19.20 Mn |
| Sep 30, 2021 | -32.08 Mn |
| Jun 30, 2021 | -31.95 Mn |
| Mar 31, 2021 | -27.52 Mn |
| Dec 31, 2020 | -21.43 Mn |
| Sep 30, 2020 | -191.51 Mn |
| Jun 30, 2020 | -23.49 Mn |
| Mar 31, 2020 | -9.47 Mn |
| Dec 31, 2019 | -16.53 Mn |
| Sep 30, 2019 | -5.53 Mn |
| Jun 30, 2019 | -7.52 Mn |